Putnam Investments’s Immunocore IMCR Stock Holding History

Putnam Investments’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-32,823	Closed	-$1.87M	–	1173
2022 Q4	$1.87M	Buy	+32,823	New	+$1.85M	﹤0.01%	738

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Putnam Investments's IMCR Position: Q1 2023 in Review

Putnam Investments sold out of Immunocore (IMCR) in Q1 2023, closing a stake of 32,823 shares — an estimated $1.87M sold.

Putnam Investments first reported a position in IMCR in Q4 2022 and held it in 1 quarter. The position peaked at $1.87M in Q4 2022. 109 funds tracked by Wall St. Rank hold IMCR as of Q1 2023.

Putnam Investments reported no remaining Immunocore position as of Q1 2023 after selling out during the quarter.
Putnam Investments sold 32,823 Immunocore shares in Q1 2023, an estimated $1.87M.
Putnam Investments first reported a position in Immunocore in Q4 2022 and held it in 1 quarter.
Putnam Investments's Immunocore position peaked at $1.87M in Q4 2022.
109 funds tracked by Wall St. Rank held Immunocore as of Q1 2023.

Based on Putnam Investments's 13F filing for Q1 2023, filed 22 May 2023.